SOD1 and amyotrophic lateral sclerosis: This study suggests that intrathecal AAV-mediated miRNA gene therapy could be developed for treatment of SOD1-linked ALS, but potentially requires the concomitant use of immunosuppresants, and additional studies with larger numbers of patients are needed.